- Home
- / PHAXIAM Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
PHAXIAM Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€0.5
2023-08-29
Market Capitalization
€48.7 M
2023-08-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Cost of goods sold | 789.0K | 527.0K | 224.0K | 226.0K | ||
| Gross profit | 3.7M | 4.8M | 3.5M | 4.0M | 6.6M | 1.3M |
| Operating expense total | 46.5M | 64.5M | 67.4M | 55.1M | 29.2M | 23.8M |
| Depreciation and amortization | 797.0K | 4.2M | 5.0M | 5.4M | 4.6M | 1.6M |
| EBITDA | (42.8M) | (59.8M) | (63.8M) | (51.1M) | (22.5M) | (21.8M) |
| EBIT | (43.6M) | (64.1M) | (68.8M) | (56.5M) | (27.1M) | (23.7M) |
| Interest income | 5.4M | |||||
| Interest expense | 28.0K | 1.5M | 2.3M | 2.7M | 1.4M | 196.0K |
| Pre tax profit | (38.2M) | (62.7M) | (73.3M) | (53.8M) | 293.0K | (23.7M) |
| Income tax expense | 2.0K | (1.0K) | 3.0K | 2.0K | 521.0K | (208.0K) |
| Net Income | (38.2M) | (62.7M) | (73.3M) | (53.8M) | (228.0K) | (23.5M) |